- Wugen, Inc. announced the closing of **$115 million** in equity financing.  **[822370_a4c29c37db5c410ba17761b5eb69adbf_0]** 
- The financing proceeds will fund the ongoing pivotal **T-RRex trial** for **WU-CART-007** in relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).  **[822370_a4c29c37db5c410ba17761b5eb69adbf_0]** **[822370_a4c29c37db5c410ba17761b5eb69adbf_1]** 
- **WU-CART-007**, an allogeneic CAR-T cell therapy, achieved a **91% overall response rate** in a global Phase 1/2 study.  **[822370_a4c29c37db5c410ba17761b5eb69adbf_0]** 
- Wugen targets a Biologics License Application (BLA) filing for **WU-CART-007** in **2027**.  **[822370_a4c29c37db5c410ba17761b5eb69adbf_0]** **[822370_a4c29c37db5c410ba17761b5eb69adbf_1]**

Emmaus Life Sciences (EMMA)